Compare CPSS & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CPSS | SLS |
|---|---|---|
| Founded | 1991 | 2012 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.3M | 208.0M |
| IPO Year | 2010 | 2007 |
| Metric | CPSS | SLS |
|---|---|---|
| Price | $8.33 | $3.77 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 14.3K | ★ 4.7M |
| Earning Date | 01-01-0001 | 04-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.69 |
| EPS | ★ 0.59 | N/A |
| Revenue | ★ $393,506,000.00 | N/A |
| Revenue This Year | $139.62 | N/A |
| Revenue Next Year | $10.58 | N/A |
| P/E Ratio | $14.13 | ★ N/A |
| Revenue Growth | ★ 11.79 | N/A |
| 52 Week Low | $6.67 | $0.95 |
| 52 Week High | $11.42 | $5.18 |
| Indicator | CPSS | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 42.56 | 50.92 |
| Support Level | $8.27 | $3.46 |
| Resistance Level | $9.20 | $3.90 |
| Average True Range (ATR) | 0.26 | 0.28 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 6.89 | 42.18 |
Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.